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NMDA Receptors (NMDARs) play key roles in synaptic physiology and NMDAR hypofunction has been
implicated in various neurological conditions. In recent years an increasing number of positive allosteric
modulators (PAMs) of NMDARs have been discovered and characterized. These diverse PAM classes vary
not only in their binding sites and GluN2 subunit selectivity proﬁles, but also in the nature of their
impacts on channel function. Major differences exist in the degree of slowing of channel deactivation and
shifting of apparent agonist afﬁnity between different classes of PAMs. Here we review the diverse
modes of potentiation by the currently known classes of NMDAR PAMs and discuss the potential con-
sequences of different types of potentiation in terms of desirable and undesirable effects on brain
function.
This article is part of the Special Issue entitled ‘Ionotropic glutamate receptors’.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Glutamate (Glu) is the principle excitatory neurotransmitter in
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vation and/or modulation of the post-synaptic neuron. Three main
classes of ligand-gated ionotropic glutamate receptors exist that are
deﬁned by the pharmacology of their Glu binding sites: alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptors (AMPARs), kainate receptors (KARs), and N-methyl-D-
aspartate (NMDA) receptors (NMDARs) (Traynelis et al., 2010).
While AMPARs and KARs are primarily involved in Glu-dependent
depolarization at excitatory synapses, NMDARs play a special role
as coincidence-detectors, allowing channel opening and depolari-
zation as well as calcium inﬂux only when the presence of Glu
within the synaptic cleft coincides with depolarization of the post-
synaptic membrane. As such, NMDARs play critical roles in
learning, memory, and cognitive function in general.
NMDARs are large tetrameric ion channels that contain two
GluN1 subunits and two GluN2 subunits (in some cases a GluN3
subunit can also be incorporated to form unconventional NMDARs).
Each subunit contains a transmembrane domain (TMD), where the
ion conductive pore and gating structures are located, a ligand
binding domain (LBD) that contains the agonist binding sites, and
an amino terminal domain (ATD). GluN2 LBDs contain the Glu
binding site, while GluN1 (or GluN3) LBDs contain the Glycine/D-
serine coagonist binding site. Four types of GluN2 subunits exit that
have distinct spatial and temporal expression patterns in the CNS:
GluN2A, GluN2B, GluN2C, and GluN2D (Akazawa et al., 1994; Laurie
and Seeburg, 1994; Monyer et al., 1994; Standaert et al., 1994;
Watanabe et al., 1992, 1994). GluN2B and GluN2D are the promi-
nent NMDARs in the prenatal mouse brain whereas GluN2A and
GluN2C are mostly not expressed until after birth. In the adult,
GluN2C is most highly expressed in the cerebellum, replacing
cerebellar GluN2B during early development. GluN2A slowly in-
creases in expression in the cortex, hippocampus, and cerebellum
starting soon after birth while GluN2B remains expressed
throughout the brain, with the exception of the cerebellum, into
adulthood. GluN2D decreases in expression during early develop-
ment, but retains expression in subcortical regions and the brain-
stem in the adult. In addition to the distinct spatial and temporal
expression patterns of the different GluN2 subunits, they also
display signiﬁcant functional differences, particularly in the rate of
deactivation following removal of Glu. GluN2A shows the fastest
deactivation kinetics, with a tau_deact <10 msec, GluN2B and
GluN2C show intermediate deactivation kinetics (tau_deact around
200e400msec), and GluN2D shows the slowest deactivation
(tau_deact > 1000msec) (Paoletti et al., 2013; Traynelis et al., 2010).
Dysfunction of NMDAR signaling has been implicated in a va-
riety of neurological and psychiatric disorders and thus there is
growing interest in developing novel drugs that target these re-
ceptors (Paoletti et al., 2013; Soto et al., 2014; Zhou and Sheng,
2013). Whereas excessive NMDAR activation is thought to play a
pathological role in certain situations, such as in stroke and some
neurodegenerative diseases, hypofunction of NMDARs may play an
important role in the pathophysiology of other diseases such as
schizophrenia. This idea originally arose from observations that
NMDAR antagonists can transiently induce the positive, negative,
and cognitive symptoms of schizophrenia in healthy individuals
(Javitt and Zukin, 1991; Krystal et al., 1994). Further studies have
found reduced expression of NMDARs (in particular the GluN2A
subunit) in parvalbumin (PV)-expressing interneurons in post-
mortem samples of schizophrenia patients (Akbarian et al., 1996;
Bitanihirwe et al., 2009). In addition, transgenic mice with
reduced GluN1 expression show schizophrenia-like behaviors
(Mohn et al., 1999). Of particular note, many of the schizophrenia
behaviors identiﬁed in mice with globally reduced GluN1 function
can be reproduced in mice with deletion of GluN1 subunits spe-
ciﬁcally from corticolimbic interneurons (Belforte et al., 2010),suggesting that deﬁcient NMDA function in interneurons may be
sufﬁcient to drive the pathophysiology of schizophrenia. Consistent
with this idea, NMDAR inhibition leads to decreased expression of
PV within PV interneurons (Behrens et al., 2007; Kinney et al.,
2006), and decreased PV levels are observed in post-mortem
schizophrenia brain samples (Hashimoto et al., 2003). Cumula-
tively this evidence has led to the hypothesis that interneuron
NMDAR hypofunction plays a central role in schizophrenia
(Gonzalez-Burgos and Lewis, 2012). At the same time mutations of
NMDAR subunits including predicted loss-of-function mutations
have been identiﬁed in epilepsy patients (Carvill et al., 2013; Lemke
et al., 2013; Lesca et al., 2013; Yuan et al., 2015) and impaired
synaptic NMDAR function occurs in animal models of Alzheimer's
Disease (Zadori et al., 2014), raising the possibility that these in-
dications may also involve NMDAR hypofunction.
Given that NMDAR hypofunction might play a role in the
pathophysiology of certain nervous system disorders, pharmaco-
logically increasing NMDAR activity could provide a therapeutic
beneﬁt. Compounds that act as agonists and directly activate
NMDARs, however, induce severe toxicity, including seizures and
neuronal death. Thus a major focus has been to identify compounds
that indirectly increase NMDAR function in order to avoid the
inherent toxicity associated with constitutive NMDAR activation.
One therapeutic approach that has been extensively investigated
for this purpose is inhibition of the GlyT1 glycine transporter
(Dunlop and Brandon, 2015; Hashimoto, 2014). Occupancy of the
glycine (Gly) binding site on NMDARs is required for Glu-
dependent activation of the receptor. While dynamic changes are
not well studied, it is typically assumed that Gly and/or D-serine are
tonically present at synapses in the brain where they act as co-
agonists and can modulate the function of NMDARs during syn-
aptic Glu release. Thus increasing Gly concentrations by inhibition
of GlyT1 should enhance Glu-dependent NMDAR synaptic currents.
Similarly inhibiting degradation of D-serine by D-amino acid oxi-
dase (DAAO) inhibitors has been explored as a means to enhance
NMDAR currents (Sacchi et al., 2013). Unfortunately, recent clinical
trials of selective GlyT1 inhibitors have failed to show efﬁcacy in
schizophrenia patients, suggesting that GlyT1 transporters may not
play a critical role in setting Gly levels at the speciﬁc synapses that
are important for schizophrenia (Balu and Coyle, 2015). Another
indirect approach to enhancing NMDAR function has been selective
positive allosteric modulators (PAMs) of mGluR5 metabotropic Glu
receptors, which can indirectly lead to enhanced NMDAR function
(Conn et al., 2014). While mGluR5 PAMs show efﬁcacy in animal
models of schizophrenia, seizures and neurotoxicity have also been
observed with some compounds, highlighting challenges with this
approach (Yang et al., 2016).
In recent years, several classes of compounds that act as direct
PAMs of NMDA receptors have been identiﬁed (Zhu and Paoletti,
2015). Such compounds represent an approach to enhancing
NMDAR function that could be independent of the local Gly-site co-
agonist concentration and independent of intracellular signal
transduction processes that indirect approaches to enhancing
NMDAR function rely on. In this review, we will describe key
properties of the different classes of NMDAR PAMs that have been
identiﬁed. In addition to discussing subunit selectivity and poten-
tial binding sites, we will pay particular attention to different PAM
modes of potentiation. We will then discuss how different prop-
erties of NMDAR PAMs could contribute to beneﬁcial or detrimental
effects in vivo.
2. Types of PAM effects
Positive allosteric modulators (PAMs) are deﬁned as modulators
that act to enhance the function of a receptor in the presence of
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absence of agonist. As such, PAMs can potentially avoid the toxicity
associated with direct agonists since they preserve the natural
pattern and timing of agonist-induced receptor activity while still
increasing the function of the receptor. In principle, there are two
types of PAM effects which can be detected in macroscopic NMDAR
current measurements: 1) PAMs can act by enhancing the
maximum activity or efﬁcacy of a receptor without altering the
agonist EC50, which wewill refer to here as a type I PAM effect, and
2) PAMs can act by shifting the agonist EC50 to lower values, which
we will refer to here as a type II PAM effect (Fig. 1a,c,e). A key
distinguishing aspect of PAMs that only have type II effects is that
they don't enhance receptor function at saturating levels of agonist,
whereas PAMs that only have type I effects enhance receptor
function equally well at all agonist levels. In practice, PAMs may
have amixture of type I and type II activities. Our deﬁnitions of type
I and type II PAM effects are based on readily observable effects on
the macroscopic agonist dose-response relationship. While these
empirical descriptions of type of PAM effects are useful for high-
lighting potentially physiologically relevant aspects of potentiation,
it is important emphasize that the observation of type I and/or type
II PAM effects does not imply an understanding of the underlying
mechanisms of a PAM. Accordingly Type I and Type II effects as
deﬁned here should not necessarily be equated with changes in the
speciﬁc kinetic parameters of mechanistic models of allostery
(Colquhoun, 1998; Conn et al., 2009).
There is an important consequence of the type II PAM effect,
which is that, regardless of underlying mechanisms, PAMs with
such effects will impact the macroscopic kinetics of receptor acti-
vation and/or deactivation. This is because deactivation and acti-
vation kinetics are related to agonist EC50 by mass action and it is
expected that EC50 ¼ tau_act/tau_deact where tau_act and tau_-
deact are the exponential time constants for activation and deac-
tivation respectively. Thus the leftward shift in the EC50 of agonist
that occurs in the presence of a type II effect implies that either
activation is faster (smaller tau_act) or deactivation is slower
(larger tau_deact) or both. In the case of NMDARs, slower deacti-
vation kinetics will impact the length of time that synaptic NMDAR
current ﬂows following the rapid removal of Glu from the synaptic
cleft and may dramatically affect the area under the curve of the
NMDAR excitatory post synaptic current (EPSC) (Fig. 1b,d,f). The
effect of this is that more calcium inﬂuxwill occur since the amount
of calcium inﬂux is proportional to the area under the curve of the
NMDAR EPSC.
It should be pointed out that shifts in agonist EC50s caused by
PAMs with type II effects do not necessarily imply direct allosteric
interactions between the PAM binding site and the agonist binding
site(s). For example, a PAM that enhances the current at saturating
Glu but not the afﬁnity of Glu can still in principle result in a left-
ward shift of the Glu EC50 curve. In the extreme case, a PAM
capable of locking the channel in the open state (following natural
Glu/Gly dependent activation) without altering Glu of Gly afﬁnity
would be expected to dramatically lower both Glu and Gly EC50s
and slow deactivation kinetics (or prevent deactivation altogether).
On the other hand, if there is a direct allosteric interaction between
the PAM and agonist binding sites, the allosteric interaction should
occur in a reciprocal fashion. Thus, a PAM that causes an increase in
Glu afﬁnity upon binding will see its own afﬁnity enhanced in the
presence of Glu. In this way, such a PAM will be sensitive to the
steady-state resting synaptic Glu concentration that is present
under physiological or pathophysiological conditions.
3. Classes of PAMs
Recently, increasing numbers of NMDAR selective PAMs havebeen discovered representing diverse structural classes (Fig. 2). In
this section we summarize information on the GluN2 subunit
selectivity, proposed binding sites (Fig. 3), and whether potentia-
tion involves type I and/or type II effects for each major class of
PAM.
3.1. PYD-106
One very well characterized NMDAR PAM series is the GluN2C-
selective pyrrolidinone PAMs exempliﬁed by PYD-106 (Fig. 2). This
PAM series was originally identiﬁed by a high-throughput screen
speciﬁcally looking for potentiators of GluN2C channels
(Zimmerman et al., 2014). Further studies revealed that PYD-106
functions as a PAM dominated by type I effects and is able to
enhance GluN2D currents by 204% while only slightly altering the
Glu EC50 (Khatri et al., 2014). In fact, the Glu EC50 is slightly
increased in the presence of PAM (rather than decreased as in the
case a PAM with type II effects). At the single-channel level, PYD-
106 increases the frequency of opening and the mean open time,
thus indicating stabilization of the open state (Khatri et al., 2014).
Structural determinants of PYD-106 PAM effects were found
nestled in the interface between the LDB and the ATD, which is a
relatively poorly conserved part of the extracellular domain,
explaining the high degree of selectivity for GluN2C. This region is
altered by a common GluN1 splice variation and as a result, GluN2C
receptors containing GluN1 exon-5 cannot be potentiated by PYD-
106. Interestingly, pyrrolidinone PAMs are also selective for dihe-
teromeric GluN1/GluN1/GluN2C/GluN2C receptors over GluN1/
GluN1/GluN2A/GluN2C triheteromeric receptors (Khatri et al.,
2014).
3.2. CIQ
The tetrahydroisoquinoline PAMs, typiﬁed by CIQ (Fig. 2), is
another well-characterized class of NMDAR PAM dominated by
type I effects. This series was originally identiﬁed in a high-
throughput screen of 100,000 compounds for their ability to
potentiate either GluN2C or GluN2D NMDARs (Mullasseril et al.,
2010). As expected for a PAM with mostly type I effects, CIQ al-
ters neither the Glu/Gly EC50s nor deactivation kinetics following
Glu washout. Furthermore, CIQ is highly selective for GluN2C and
GluN2D channels, showing no ability to potentiate either GluN2A
or GluN2B. Further studies have demonstrated structural de-
terminants of CIQ located in the transmembrane domain of
GluN2C/D, where speciﬁc residues in the GluN2 M1 TM helix are
critical to PAM action and afﬁnity (Ogden and Traynelis, 2013).
Most of these residues are highly conserved between GluN2 sub-
units, though one residue, GluN2D Thr592 (or GluN2C Thr565), is
an isoleucine residue in both GluN2A and GluN2B. The fact that CIQ
fails to potentiate GluN2D receptors with a T592I mutation sug-
gests that this single residue deﬁnes the NMDAR selectivity pattern.
Residues in the linker between the S1 part of the LBD and the M1
helix (known as the pre-M1 region) also can alter the ability of CIQ
to potentiate the channels when mutated, although these residues
have been proposed to not make direct contacts with the PAM but
rather alter the ability of CIQ to induce down-stream structural
changes that alter channel gating. At the single-channel level, CIQ
acts by increasing the opening frequency rather than by stabilizing
the open-state of the channel (Mullasseril et al., 2010).
3.3. Spermine
NMDARs are modulated by endogenous polyamines of which
spermine is the most well studied (Fig. 2). In addition to inhibiting
NMDARs via a voltage-dependent pore block mechanism (Rock and
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potentiation effect is speciﬁc to GluN2B, making spermine a
GluN2B-selective NMDAR PAM, whereas the inhibitory effect of
spermine occurs equally with all NMDARs. Spermine potentiates
GluN2B by shifting the pH-dependence of proton inhibition of
NMDARs (Traynelis et al., 1995). As a result, spermine only poten-
tiates GluN2B when the pH is in the physiological range (pH 6e8).
Under conditions where pH > 8.0, spermine only functions as a
pore blocker whereas when pH < 6.0, GluN2B is fully inhibited even
in the presence of spermine. In addition to shifts in the pH-
dependence of proton inhibition, spermine also reduces the Gly
EC50 by a factor of ~3-fold without altering the Glu EC50
(Benveniste and Mayer, 1993; McGurk et al., 1990). As expected, the
deactivation kinetics following removal of Gly in the presence of
saturating NMDA is slowed signiﬁcantly in the presence of sper-
mine, while the deactivation kinetics following removal of NMDA
in the presence of Gly is not affected (Benveniste and Mayer, 1993).
Thus, spermine potentiates GluN2B receptors by two apparently
distinct mechanisms. Since spermine causes an increase in Gly
potency, its effects involve type II PAM action with respect to Gly.
However, since Glu is the agonist that is rapidly removed from the
synapse following synaptic release, deactivation kinetics should not
be signiﬁcantly altered physiologically. Therefore, spermine should
be viewed as a PAM dominated by type I effects with respect to Glu.
Extensive mutational analysis has demonstrated that structural
determinants for spermine lie within the ATD at the lower lobe of
the GluN1/GluN2B subunit interface (Mony et al., 2011). Electro-
static interactions between charged residues present in the ATD
lower lobe have been proposed to maintain the ATD in a state that
favors a low open probability of the pore. By stabilizing the GluN1/
GluN2B interface at this lower lobe, spermine has been proposed to
force the channel into a higher open probability state, thus causing
potentiation (Mony et al., 2011). Interestingly, the presence of exon-
5 in the GluN1 ATD occludes the effects of spermine, making
spermine speciﬁcally selective for GluN2B-containing NMDARs
that lack exon-5 (Traynelis et al., 1995).
3.4. Pregnenolone sulphate
In addition to modulation of GABAA receptors, neurosteroids
can modulate NMDARs. Pregnenolone sulphate (PS) is the most
widely studied neurosteroid potentiator of NMDARs (Fig 2). Studies
with oocyte NMDAR expression showed that PS potentiates
GluN2A and GluN2B NMDARs and inhibits GluN2C and GluN2D
NMDARs (Malayev et al., 2002). Subsequent studies using rapid
perfusion in HEK cells demonstrated additional complexity in the
effects of PS on GluN2B NMDARs, with both inhibitory (with fast
kinetics), and potentiating (with slower kinetics) effects observed
(Horak et al., 2006). Thus, subtype selectivity of pregnenolone
might be the result of the balance between differential afﬁnities for
inhibitory and potentiating binding sites at NMDARs with different
subunit compositions. In contrast, inhibitory neurosteroids, such as
the related neurosteroid pregnanolone sulphate (3alpha5betaS)
that inhibit all 4 GluN2 subtypes equally, would be predicted to
bind primarily to the inhibitory site.
The location of the PS binding site that is responsible for PAM
effects is still unclear, but appears to be distinct from the spermine
binding site since unlike spermine, PS-dependent potentiation
does not depend on pH nor the presence of the GluN1 exon-5
(Horak et al., 2006; Jang et al., 2004), and PS is still capable of
potentiating NMDARs in the presence of saturating concentrations
of spermine (Park-Chung et al., 1997). This evidence for distinct
binding sites is consistent with the chemically distinct nature of the
compounds with spermine being highly charged and PS very hy-
drophobic. The inhibitory neurosteroid binding site is also likelydistinct from the PAM site since 3alpha5betaS inhibits with the
same IC50 in the presence and absence of 200 mM PS (Park-Chung
et al., 1997). By generating a series of GluN2B/GluN2D chimeric
constructs, subunit differences in the J and K helices present in the
LDB were found to be responsible for the selectivity of PS-
dependent potentiation for GluN2B vs GluN2D (Horak et al.,
2006; Jang et al., 2004). It was thus proposed that the binding
site might be at the GluN1-GluN2B subunit interface within the
LBD. However, an alternative interpretation of existing data sug-
gests a TMD binding site could also be possible (Mony et al., 2009).
Interestingly PS potentiation is much less effective when PS is
applied in the presence of agonists, than when pre-applied before
agonist application suggesting higher afﬁnity binding to the inac-
tive NMDAR conformation (Horak et al., 2004, 2006). PS has been
shown to increase both the NMDAR current at saturating agonists
as well as the EC50s of Glu and Gly at GluN2A and GluN2B NMDARs,
and has been shown to both increase the peak response during
agonist application and signiﬁcantly slow deactivation following
agonist withdrawal (Bowlby, 1993; Ceccon et al., 2001; Horak et al.,
2006; Malayev et al., 2002). This indicates that PS functions as a
mixed PAM with both type I and type II PAM effects.
3.5. Oxysterols
Aside from PS, another class of neurosteroid NMDAR PAMs is the
oxysterol cholesterol derivatives (Fig. 2). The oxysterol 24(S)-
hydroxycholesterol (24(S)-HC) is the most abundant cholesterol
metabolite found in the brain. 24(S)-HC, as well as its synthetic
derivatives, SGE201 and SGE301, have been shown to be GluN2
subunit non-selective PAMs of NMDARs (Paul et al., 2013). SGE-201
strongly increases the NMDAR current at saturating Glu and Gly,
with only very minor effects on Glu potency (Linsenbardt et al.,
2014), and no appreciable slowing of deactivation is evident
following agonist removal in the presence of 24(S)-HC or SGE-201
(Paul et al., 2013), indicating that oxysterols act as non-selective
NMDAR PAMs dominated by type I PAM effects. While little is
known about the oxysterol binding site, lack of occlusion in pre-
treatment experiments suggests oxysterols may have a distinct
binding site from PS, and action that appears to be consistent with
ﬁrst partitioning in to the plasma membrane could potentially
suggest a TMD binding site (Linsenbardt et al., 2014; Paul et al.,
2013).
3.6. UBP compounds
A series of naphthoic and phenanthroic acids has been described
to act as PAMs of certain NMDARs (Fig. 2). The various compounds
exhibit variable proﬁles of potentiation and inhibition of the
different GluN2 subunits (Costa et al., 2010; Irvine et al., 2012). For
example, UBP512 causes a small potentiation of GluN2A NMDARs,
has minimal effects on GluN2B, and inhibits GluN2C and GluN2D.
UBP551 potentiates GluN2D while inhibiting GluN2A, GluN2B, and
GluN2C. UBP710 and UBP714 potentiate GluN2A and GluN2B with
minimal effects on 2C and 2D. UBP646 shows potentiation of all
GluN2-containing NMDARs. Although the relatively low potency
and limited solubility prevent full characterization of the selectivity
of some of these compounds at saturating PAM concentrations,
these compounds appear to reﬂect a binding sitewith rich potential
for subunit selectivity. While a precise binding site has not been
deﬁned, based on potentiation of NMDARs with an ATD deletion
and analysis of chimeric channels, a possible LBD binding site has
been suggested. While it was shown that the NAM effects don't
compete with Gly or Glu, insufﬁcient data is available to determine
if these compounds act via type I and/or type II PAM effects.
However the observation that UBP512 potentiation of GluN2A
Fig. 1. Different types of NMDAR PAM effects (type I vs type II vs mixed). a,b. Type I effects enhance the maximum NMDAR current without altering that agonist EC50 and don't
slow deactivation kinetics. c,d. Type II effects shift the agonist EC50 to lower values and generally slow deactivation kinetics. e,f. Mixed type I/II PAMs have a mixture of type I and
type II activities. Simulated NMDAR currents are shown as relative currents normalized to the current at saturating Glu/Gly in the absence of PAM.
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to low agonist concentrations (Costa et al., 2010) is not consistent
with type II effects and suggests potential type I effects.3.7. GNE PAMs
Recently we described a novel series of NMDAR PAMs contain-
ing a thiazolo-pyrimidinone scaffold (Hackos et al., 2016; Volgraf
et al., 2016) (Fig 2). This series was identiﬁed in a high-
throughput screen of 1.4 million compounds that were tested for
their ability to potentiate GluN2A containing NMDARs. Further
medicinal chemistry efforts led to the identiﬁcation of GNE-6901
and GNE-8324 which show selectivity for GluN2A containing
NMDARs and bind to the LBD at the GluN1-GluN2A subunit inter-
face (Fig. 4a,c,d). Interestingly, subtle chemical modiﬁcations led tothe generation of PAMs dominated by type I PAM effects, such as
GNE-6901, which only minimally increases Glu potency, as well as
mixed PAMs with both type I and type II PAM effects such as GNE-
8324, which signiﬁcantly increase Glu potency (Fig. 5). As expected,
GNE-8324 signiﬁcantly slows deactivation kinetics while GNE-6901
has only minimal effects on deactivation (Fig 5). Interestingly,
despite the fact that PAMs of this series bind to a site directly be-
tween the Glu and Gly binding sites within the LBD dimer, only Glu
potency is affected.
The GluN2A subunit selectivity of the GNE PAMs is due to a
single amino acid that is adjacent to the binding site, V783. This
residue is valine in GluN2A, phenylalanine in GluN2B, and leucine
in GluN2C and GluN2D. Steric clashes with the PAMs occur in the
case of the larger phenylalanine and leucine side-chains, giving rise
to the subtype selectivity. Interestingly, this same residue also
Fig. 2. The chemical structures of different NMDAR PAM classes. Shown are the PAMs discussed in this review, which represent the currently known classes of NMDAR PAMs.
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negative allosteric modulator (NAM) that binds to the same
GluN1-GluN2A subunit-interface binding site (Hansen et al., 2012).
We recently solved a crystal structure of compound 6 (Bettini et al.,
2010), a close analog of TCN-201, in complex with the LBD, further
verifying the location of the binding site for this class of NAM at the
GluN1-GluN2A subunit interface within the LBD (Hackos et al.,
2016). TCN-201 is known to work by decreasing the potency of
the GluN1 agonists Gly and D-serine (Edman et al., 2012; Hansen
et al., 2012), though it is not clear from the crystal structure how
this happens exactly as the Gly binding site does not appear
signiﬁcantly perturbed upon NAM binding at the structural level
(Fig. 4a,b). The GNE PAMs, such as GNE-6901 and GNE-8324, bind
to the same region but with a different orientation (Fig. 4c,d). We
speculate that by binding in this orientation, the PAMs stabilize the
GluN1-GluN2A subunit interface in such away to increase the open
probability of the channel, even in the presence of saturating Glu
and Gly (as is observed). How this occurs at the structural level,
however, is not clear since we don't observe major differences
between PAM-bound and un-bound structures. Furthermore, why
some GNE PAMs such as GNE-8324 are able to increase the Glu
potency while others such as GNE-6901 showminimal increases inGlu potency is also not clear from the structures. Interestingly,
however, the GNE PAMs reposition the side chain of Y535, a residue
in GluN1 that is thought to stabilize the Glu-bound state and alter
Glu EC50 and deactivation kinetics (Furukawa et al., 2005), though
such Y535 repositioning occurs in the case of both GNE-6901 and
GNE-8324 binding (Hackos et al., 2016). Nonetheless, the fact that
different modulators that bind to the GluN1-GluN2A subunit
interface within the LBD can have such distinct effects on channel
function indicate the future value of this binding site for selectively
modulating NMDARs via diverse mechanisms.
4. Consequences of subtype selectivity
While many of the speciﬁc PAMs discussed do not represent
fully drug-like molecules due to limitation of potency, solubility,
pharmacokinetics, and potential off target effects, these classes of
PAMs demonstrate the diversity of properties that could be found
in a potential drug (Table 1). One key determinant of the conse-
quences of in vivo PAM treatment will be the GluN2 subunit
selectivity. For example potentiation of 2A and 2B containing
NMDARs could have broad effects throughout the brain given the
widespread expression of these subunits in the adult. GluN2A
Fig. 3. The structure of the NMDA receptor showing potential and known PAM binding sites. The GluN1 subunit is shown in gold and the GluN2 subunit is shown in silver. The
other GluN1 and GluN2 subunits that make up the tetrameric channel are shownwith a transparent surface rendering. The three major domains that make up the NMDAR channel
are indicated on the left (ATD, LBD, and TMD). The binding sites of Glu, Gly, and PAM classes with well characterized binding sites are indicated. The full length NMDAR crystal
structure shown is the Xenopus GluN1/GluN2B receptor (PDB: 4TLL (Lee et al., 2014),).
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cortico-limbic areas as these NMDARs are found at synapses in the
form of both di-heteromeric GluN1/2A/2A and tri-heteromeric
GluN1/2A/2B NMDARs (Gray et al., 2011; Rauner and Kohr, 2011;
Soares and Lee, 2013; Tovar et al., 2013). While di-heteromeric
GluN1/2B/2B NMDARs are found at extrasynaptic locations in
excitatory pyramidal neurons (Harris and Pettit, 2007; Papouin
et al., 2012), these receptors have synaptic functions in in-
terneurons (Hanson et al., 2013). Thus PAMs that affect GluN2B-
containing NMDARs should also have broad effects.
Arguments could be made for or against the desirability of
potentiating GluN2B subunits. On one hand, transgenic over-
expression of GluN2B results in mice with enhanced synaptic
plasticity and learning and memory (Tang et al., 1999; Wang et al.,
2009), which could suggest value in enhancing GluN2B function.
However it's important not to equate the effects of over-expression
with pharmacological enhancement. As the cytoplasmic tail of
GluN2B NMDAR participates in organization of the postsynaptic
complex and plays critical roles in signaling (Foster et al., 2010;
Martel et al., 2012; Sheng and Pak, 1999), increasing the abun-
dance of this subunit beginning during early development could
have very different effects than pharmacologically enhancing re-
ceptors with endogenous subunit compositions. At the same time,
data using GluN2B antagonists which are much more effective on
GluN1/2B/2B diheteromers compared to GluN1/2A/2B trihe-
teromers (Hansen et al., 2014; Hatton and Paoletti, 2005; Stroebel
et al., 2014), has implicated GluN2B-containing NMDARs in medi-
ating excitotoxic cell damage and death (Costa et al., 2012; Liu et al.,
2007; Ronicke et al., 2011; Zeron et al., 2002). Hypothesis for the
damaging effects of GluN2B NMDAR over-activation include pref-
erential coupling of GluN2B-containing NMDARs to signaling
pathways involved in cell death, and/or the preferential extra-
synaptic location of these receptors (Hardingham and Bading,
2010; Martel et al., 2012; Zhou and Sheng, 2013). Thus the in vivo
consequences of potentiating GluN2B subunit-containing NMDARs
could involve a mixture of effects on synaptic triheteromers and
extrasynaptic diheteromers, with theoretical bases for both bene-
ﬁcial and deleterious consequences.Interestingly, human genetics implicates both GluN2A and
GluN2B in various conditions including attention deﬁcit hyperac-
tivity disorder, autism spectrum disorder, epilepsy, intellectual
disability, and schizophrenia (Yuan et al., 2015). In particular, the
numerous GluN2A mutations that have been found in epilepsy-
aphasia syndromes provide interesting insight. While some
GluN2A mutations are clearly loss-of-function, studies focusing on
missense mutations of residues with expected roles in NMDAR
activation have demonstrated multiple examples of gain-of-
function (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013;
Marwick et al., 2015; Serraz et al., 2016; Yuan et al., 2014). That
both loss- or gain-of-function of GluN2A mutations can lead to
epilepsy suggests that while GluN2A potentiation could be bene-
ﬁcial in cases of NMDAR hypofunction, negative consequences of
excessive potentiation could also be possible.
While GluN2A and GluN2B are widely distributed in the adult
brain, the more restricted distribution of GluN2C and GluN2D in
subcortical and brainstem structures suggest the consequences of
PAMs targeting these subunits will be more speciﬁc. For example
CIQ delivery to the amygdala facilitates the retention of fear and
extinction learning in mice (Ogden et al., 2014), and delivery to the
subthalamic nucleus (STN) can enhance STN neuron spike rates
in vivo (Swanger et al., 2015). This suggests GluN2C/D potentiation
could both enhance emotional memory via the amygdala, and alter
function of basal ganglia circuitry, which could potentially be
beneﬁcial in the context of movement disorders like Parkinson's
disease.
While cortical and hippocampal excitatory neuron expression is
restricted to GluN2A and GluN2B, there is evidence for expression
of all four GluN2 subunits in forebrain interneurons (Monyer et al.,
1994). Furthermore, functional roles for synaptic GluN2A and
GluN2B have been shown in interneurons (Hackos et al., 2016;
Hanson et al., 2013) and functional roles for interneuron GluN2C
and GluN2D are also likely. For example, the expression of GluN2C
and GluN2D in interneurons could explain the ability of systemic
CIQ treatment to oppose the behavioral impacts of treatment with
the psychotomimetic NMDAR pore blocker MK-801 (Suryavanshi
et al., 2014), which can alter circuit function via reduction of
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activation of GluN2A, GluN2B, GluN2C, or GluN2D-containing
NMDARs could all potentially boost inhibition and be of potential
use in cases of interneuron hypofunction. In addition to schizo-
phrenia (Gonzalez-Burgos and Lewis, 2012), interneuron hypo-
function has been identiﬁed as driving pathophysiology in animal
models of epilepsy, and Alzheimer's disease (Verret et al., 2012;
Yamakawa, 2009). Therefore interneurons should be considered
as potential key targets of NMDAR PAM action.
5. Consequences of type I vs type II PAM effects
While existing data contrasting PAMs with Type I vs Type II
effects is limited, it is interesting to consider potential differences inFig. 4. Crystal structures of NMDA modulators that bind to the GluN1/GluN2A LBD dime
LBD with bound NAM (compound 6, similar to TCN-201) (PBD: 5H8N). c. LBD with bound
GluN1 is shown in gold, GluN2A is shown in silver, Gly is shown in blue, and Glu is shownphysiological impacts that could arise from the different types of
PAM effects. A key difference between the types of PAMs is that
PAMs dominated by type I effects could better maintain the tem-
poral ﬁdelity of NMDAR signaling because they don't slow deacti-
vation like PAMs with strong type II effects. In theory, a longer-
lasting NMDAR ESPC might deleteriously affect the ﬁdelity of syn-
aptic timing, especially in situations with high frequency synaptic
activity, such as during network oscillations. Another difference is
that while PAMs with type I effects should enhance the peak syn-
aptic current regardless of agonist concentrations, PAMs with
purely type II effects should be unable to enhance peak currents at
synapses where agonist concentrations are saturating during syn-
aptic transmission. At the same time the observation that the po-
tency of a PAM with type II effects can be dependent on the Glur interface. a. Agonist bound LBD in the absence of bound modulator (PBD: 5H8F). b.
GNE-6901 (PBD: 5H8R). d. LBD with bound GNE-8324 (PDB: 5H8Q). For all structures,
in red.
Fig. 5. GNE-6901 vs GNE-8324 properties. a. GNE-6901 is a GluN2A-selective PAM dominated by type I effects, showing enhancement of Glu-activated currents without signif-
icantly slowing deactivation kinetics. b. GNE-8324 is a GluN2A-selective mixed type I/II PAM that slows deactivation kinetics. c. GNE-6901 alters peak currents without signiﬁcantly
shifting the Glu EC50. d. As expected for a PAM with both type I and type II activities, GNE-8324 both enhances peak current and shifts the Glu EC50 to the left.
Table 1
Properties of different NMDAR PAMs. The selectivity proﬁle, type of PAM effects,
and sites of action for the key PAMs described in this review are listed. As described
in the text, PAMs with purely type I PAM effects are deﬁned as modulating the
maximal current while PAMs dominated by type II effects modulate agonist EC50
and slow deactivation. Cases where robust Type I or Type II effects have been
demonstrated are speciﬁed. Sites of action are only speciﬁed when binding sites are
especially well deﬁned by mutational analysis (or by a co-crystal structure as in the
case of the GNE compounds).
Compound Selectivity Type I effect Type II effect Site of action
PYD-106 2C Yes No LBD/ATD
CIQ 2C,2D Yes No TMD
Spermine 2B Yes Yes (Gly only) ATD
PS 2A,2B Yes Yes (Glu&Gly) ?
Oxysterols 2A,B,C,D Yes No ?
UBP cmpds various Yes? No? ?
GNE-6901 2A Yes Small LBD
GNE-8324 2A Yes Yes (Glu) LBD
D.H. Hackos, J.E. Hanson / Neuropharmacology 112 (2017) 34e4542concentration (Hackos et al., 2016) could also contribute to differ-
ences in PAM effects at different synapses. In particular, synapses
with high resting Glu levels could allow such PAMs to bind prior to
synaptic transmission. Thus both resting and peak synaptic Glu
concentration levels could inﬂuence the efﬁcacy of PAMs with type
II effects. As Glu transporter density varies throughout brain re-
gions (Bar-Peled et al., 1997), and can even vary at synapses made
by the same neuronal population onto different postsynaptic target
populations (Chaudhry et al., 1995), it is possible that synaptic Glu
concentration proﬁles vary between different types of synapses.
Therefore there is potential for PAMs with type II effects that
depend on Glu concentration to have variable proﬁles of action
across different synapses.
A striking example of synapse-dependent effects is the mixed
type I/II GluN2A PAM GNE-8324 that binds with higher potency at
high Glu concentrations (Hackos et al., 2016). This property sug-
gests much lower PAM concentrations could be effective at syn-
apses where ambient Glu levels are higher and therefore allow
higher levels of PAM binding prior to synaptic Glu release. Strik-
ingly, at concentrations tested in vitro, GNE-8234 potentiates syn-
apses on hippocampal interneurons, but not pyramidal neurons,
while a PAM dominated by type I PAM effects, GNE-6901 (which
lacks a pronounced dependence of PAM afﬁnity on Glu concen-
tration) potentiates both type of synapses equally. This is consistent
with the hypothesis that hippocampal interneuron synapses have
higher resting Glu concentrations, resulting in greater GNE-8324effects. The differential effects of the PAMs was also manifest at
the circuit level: While GNE-6901 could enhance synaptic plasticity
of synapses onto pyramidal neurons, GNE-8324 impaired synaptic
plasticity, apparently due to the dominance of the effects on in-
terneurons which can oppose synaptic plasticity induction via
polysynaptic inhibition (Hackos et al., 2016). Consistent with the
ability of PAMs with type I PAM effects to have impacts that are
dominated by robust effects on pyramidal neurons, LTP is enhanced
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desirable in some disease contexts, in theory PAMs that could
selectively enhance interneuron function could also be beneﬁcial in
the context of diseases associated with interneuron hypofunction,
which as discussed include schizophrenia, epilepsy and Alz-
heimer's disease (Gonzalez-Burgos and Lewis, 2012; Verret et al.,
2012; Yamakawa, 2009).
Along with some potential beneﬁts, there are also undesirable
consequences of the type II mode of action. In addition to degrading
temporal ﬁdelity of NMDAR signaling, another potentially negative
consequence of the type II PAM effect is that shifting agonist EC50
could lead to over-activation of NMDARs by ambient Glu. In the
extreme case, given sufﬁciently high ambient Glu and a sufﬁciently
large EC50 shift, a PAM dominated by type II effects could act like an
agonist. In fact with GNE-8324, in cell-line experiments, we
observed some degree of agonist-like activity in the presence of Gly
prior to Glu application (Hackos et al., 2016). In practice it is very
difﬁcult to distinguish true agonist activity of a compound from
activation by low levels of contaminating agonist when PAM
binding makes NMDAR more sensitive to Glu. Regardless of this
distinction, it is clear that causing large fold shifts of the agonist
EC50 should be sufﬁcient to cause a PAM to act like an agonist
under physiological conditions, as some level of ambient agonist
will be present in most circumstances. This undesirable aspect of
the type II PAM effect has been observedwithmGluR5 PAMs, where
low fold shift compounds achieve a better therapeutic index while
high fold shift compounds cause seizures (Yang et al., 2016). As a
mechanism of mGluR5 PAM efﬁcacy is proposed to be enhancing
NMDAR function, it will be interesting to test if a similar relation-
ship between fold shift (degree of type II activity) and therapeutic
index exists for NMDAR PAMs.6. Conclusions future directions
Overall the increasing number NMDAR PAM classes that have
been discovered has opened up possibilities for the design of
therapeutics that target NMDARs in situations where hypofunction
of these receptors drives neurological dysfunction. While distinct
binding sites allow for diverse subunit selectivity proﬁles, it is clear
that not only subunit selectivity, but also the nature of PAM action
(type I vs. type II vs. mixed type I/II) will have major consequences
on the impacts of PAMs in brain circuits. As existing PAMs are
characterized and more PAMs are discovered, it will be critical to
examine the properties of potentiation, including PAM effects on
deactivation and agonist EC50s, and to correlate these properties
with effects at the levels of circuit function and behavior. Beyond
the simple attributes of type I and type II effects, mechanistic in-
formation from single channel recordings and detailed kinetic
models will also be needed to provide additional information into
PAM mechanisms of action. Deep understanding of PAM binding
sites and mechanisms of action will provide the tools necessary to
enable custom design of NMDAR PAMs with the particular prop-
erties best suited to their therapeutic application. Ultimately
distinct proﬁles of subunit selectivity and potentiation mode may
be required to have the best safety and efﬁcacy proﬁle in the
context of different indications.
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